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Hypertension (HPT) is regarded as one of the most important 
cardiovascular risk factors globally, estimated to affect more than 
one billion people. Globally, non-communicable diseases (NCDs) 
are responsible for 70% of deaths, the majority from cardiovascular 
diseases such as cerebrovascular disease and myocardial infarction. [1,2] 
HPT remains a major contributor to premature mortality globally.[3,4] 
It is estimated that >80% of the burden associated with HPT is now 
carried by low- and middle-income countries, with Africa having 
the highest prevalence of HPT among adults worldwide.[5] Elevated 
blood pressure and HPT account for more deaths globally than 
any of the other cardiovascular risk factors (smoking, obesity and 
dyslipidaemia).[6]
The current COVID-19 pandemic highlights the critical 
interaction between communicable diseases and NCDs worldwide. 
Several studies have recently demonstrated that HPT, obesity and 
diabetes mellitus (DM) are important comorbidities associated with 
increased mortality risk in patients with COVID-19 infection. [7-10] 
The prevalence of NCDs in patients with COVID-19 infection has 
been shown to range from 15% to 33% for HPT and from 8.4% 
to 20% for DM.[11-15] Wang et al.[11] and Zhou et al.[12] showed that 
the prevalence of severe COVID-19 infection was 58% and 48%, 
respectively, in patients with HPT and 22% and 31%, respectively, in 
patients with DM. Another study showed that the presence of HPT in a 
COVID-19-infected patient increased the odds of mortality by a factor 
of three.[16,17] In addition, various studies have shown that obesity is an 
independent risk factor for severe COVID-19 infection.[18,19]
Results from the South African National and Nutrition Examination 
Study demonstrated that 35.1% of individuals (35.2% of males 
and 34.7% of females) aged >15 years in South Africa (SA) were 
hypertensive,[20] and that 91.1% of the SA hypertensive population 
were unscreened, undiagnosed, untreated or uncontrolled. A mere 
8.9% of the total SA hypertensive population was shown to be 
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Background. Hypertension (HPT) and its complications continue to pose a global threat and contribute to premature mortality worldwide. 
The adverse interactions between HPT, obesity and COVID-19 are currently being witnessed globally and represent a collision of 
pandemics. Understanding the burden that this non-communicable disease (NCD) poses in KwaZulu-Natal (KZN) Province, South Africa 
(SA), would help in developing improved public healthcare strategies.
Objectives. To describe the burden of HPT in all the districts of KZN over a 6-year period.
Methods. HPT data are routinely collected from all KZN public health facilities (both clinics and hospitals) as part of the District Health 
Information System (DHIS). In this retrospective study, we accessed HPT records from the DHIS over a period of 6 years (2014 - 2019, 
inclusive). Data collected included the number of patients screened, diagnosed and initiated on therapy for HPT, together with the number 
of obese patients.
Results. The slopes for HPT screening were positive at both clinics and hospitals in KZN (considerably more at clinics than hospitals, 
with a difference in elevations of slopes of p<0.001), with a significantly greater percentage of the population having been screened at rural 
clinics than at hospitals (difference in elevation of slopes p<0.001). A significantly greater number of patients aged <40 years (p<0.001) 
were being screened for HPT at clinics than at hospitals (2017/18, 2018/19, 2019/20), while hospitals screened considerably more patients 
aged ≥40 years in 2017 - 2018 (p<0.001). The numbers of new hypertensives diagnosed and having treatment initiated were on an upward 
slope at both clinics and hospitals, with clinics having a greater elevation of slope than hospitals (p<0.001), irrespective of patient age. 
A significantly greater number of patients aged ≥40 years (p<0.05) were diagnosed with HPT at both clinics and hospitals in KZN (2017/18, 
2018/19, 2019/20). KZN clinics remained the first port of call for known hypertensives throughout the study period. Obesity was prevalent 
at both clinic and hospital level, although figures were significantly higher at clinics. Over 80% of the obesity burden was carried by the 
rural clinics and hospitals.
Conclusions. Screening, diagnosis, treatment initiation and chronic management of HPT occur mainly at rural clinic level. The SA 
government needs to heed these findings and redirect resources (staffing and equipment) to this level. The prevalence of obesity was highest 
at rural healthcare facilities (clinics more than hospitals). More needs to be done to combat the obesity pandemic if we are to win the battle 
against NCDs (HPT and diabetes mellitus). A significant number of patients aged <40 years are being screened for HPT, which bodes well 
for the province, as early diagnosis and treatment of HPT are vital to prevent complications.
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controlled. In contrast, estimates from the USA indicated that 29.1% 
of their population were hypertensive, with over half of these patients 
(52%) being classified as controlled.[21]
SA currently has the highest prevalence of HIV infection globally 
(13.5%).[22] The combination of HIV/tuberculosis (TB) and NCDs 
in the form of HPT and DM poses a massive problem for both 
individual patients and the country. Brennan et al.[23] showed that 
HPT was common among patients who were HIV-infected, those 
who were on antiretroviral therapy, and those who were overweight 
or obese.
SA has the highest prevalence of HPT in sub-Saharan Africa 
(SSA), and also the greatest number of patients whose blood pressure 
is suboptimally controlled despite being on treatment.[24] Rapid 
urbanisation has been postulated as one of the reasons for the high 
prevalence of HPT in SA.[25] Addo et al.,[26] in a systematic review of 
25 studies conducted in SSA, concluded that the majority of patients 
with HPT lived in urban areas. The latest Statistics South Africa 
survey showed that two-thirds of the SA population live in urbanised 
areas.[22] HPT is not exclusively limited to urban areas, as Ntuli et al.[27] 
found that there is also a high prevalence of HPT in rural patients. 
They suggested that prevention strategies need to be developed for 
rural areas as much as for urban ones. It must also be noted that HPT 
in black African patients is generally more severe, and often more 
resistant to therapy, than that in other ethnic groups.[26,28]
Added to this cauldron of communicable diseases and NCDs, SA 
has the highest rate of obesity in SSA.[22] Obesity is known to be one 
of the causes of HPT.[29,30] Berry et al.[20] showed that the prevalence of 
HPT was highest in patients with higher body mass indices (BMIs), 
highlighting the fact that weight is a risk factor for development 
of HPT. Harris et al.[30] found that the odds of developing HPT 
were much higher (1.7 - 3.4 times) in obese compared with lean 
individuals. Importantly, it has also been shown that weight loss 
results in a drop in blood pressure.[31] Majane et al.[32] showed 
in black African patients that for every 15 cm increase in waist 
circumference there was an increase in systolic and diastolic blood 
pressure of ~3  mmHg. They also stated that HPT and obesity work 
synergistically in increasing cardiovascular damage. The Heart of 
Soweto study found that obesity was the most important aetiological 
factor associated with hypertensive heart disease.[33] Obesity has been 
shown to be associated with living in urban areas.[34] Being obese also 
carries with it the risk of developing another heavyweight NCD in the 
form of insulin resistance and DM.[35]
The World Health Organization has stated that the burden of 
NCDs in SA is two to three times higher than that in developed 
countries.[36] SA’s NCD burden is on an increasing trend in rural 
areas as well.[37] It is estimated that NCDs (DM, heart disease and 
stroke) cost the SA government ~USD1.88 billion between 2006 
and 2015.[38] Kenge and Mchiza[39] pointed out that NCD costs are 
both tangible (work absenteeism, decreased productivity and time 
losses) and intangible (decreased quality of life, pain and suffering) 
in nature. 
In 2011, together with many other countries, SA agreed to 
introduce the Global Action Plan, which aimed to prevent and 
control NCDs and decrease premature NCD mortality by at least 
one-third.[1]
Objectives
To describe the burden of HPT in all the districts of KwaZulu-Natal 
(KZN) Province, SA, over a 6-year period.
Methods
KZN is the second most populated province in SA and has a high 
burden of both communicable diseases and NCDs.[10] KZN is divided 
into one metropolitan municipality (eThekwini) and 10 district 
municipalities, each having healthcare facilities ranging from clinics 
to hospital level.
HPT data are collected routinely from all public health facilities in 
KZN, as part of the District Health Information System (DHIS). The 
data are then aggregated at facility level, and no individual patient data 
are used. The data are managed by the Data Management Unit of the 
KZN Department of Health, which makes them available on request.
In this retrospective study, we accessed records from the DHIS 
over a period of 6 years (2014 - 2019, inclusive).
Data collection
After ethics approval for the study had been obtained from the 
local ethics review committee (Biomedical Research and Ethics 
Committee, ref. no. BREC 1266/2020) and the KZN Department of 
Health, data were accessed from the DHIS records.
For the purposes of this study, the following indicators were 
analysed for each district of KZN:
• For the time periods 2014/15, 2015/16 and 2016/17, the following 
DHIS data elements were analysed for all provincial clinics and 
hospitals:
 ° number of clients screened for HPT
 ° number of defaulters
 ° number of patients who were started on antihypertensive 
medications.
The data elements collected for HPT were modified by the DHIS in 
2017.
• For the time periods 2017/18, 2018/19 and 2019/20, the following 
DHIS data elements were analysed for all provincial clinics and 
hospitals:
 ° number of patients aged <40 years screened for HPT
 ° number of patients aged ≥40 years of age screened for HPT
 ° number of new HPT cases in patients aged ≥40 years
 ° number of new HPT cases in patients aged <40 years
 ° number of visits by patients with known HPT
 ° number of patients with BMI >30 kg/m2.
The location of the district was classified as urban or rural. Urban 
areas comprised urban and semi-urban settings, while the term rural 
described rural and semi-rural settings.
Statistical analysis
The data were interrogated to assess the current burden of HPT in 
KZN using simple descriptive statistics. The weighted means test was 
used to calculate statistical significance. A p-value <0.05 was regarded 
as statistically significant. A comparison in terms of the rates per 
100 000 population was done using the slopes and elevations test.
Results
Fig. 1 illustrates the overall HPT screening pattern for clinics and 
hospitals at all public healthcare facilities in KZN between 2015 and 
2020. No significant difference in the slopes of number of patients 
screened for HPT at clinic v. hospital level was found (p=0.971); 
however, there was a significant difference between these slopes in 
terms of elevation (p<0.001).
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Further subdivision of patients screened 
for HPT into those aged <40 years and 
≥40  years confirmed that the majority of 
HPT screening in KZN is being conducted 
at clinic level, irrespective of patient age 
(Figs 2 and 3).
Table 1 shows that clinics were screening 
a significantly higher number of patients 
aged <40 years for HPT than older patients. 
However, this trend was not seen at hospital 
level, where considerably more patients aged 
≥40 years were screened in the 2017/18 
period.
Fig. 4 illustrates the total number of new 
hypertensives diagnosed at the various KZN 
public healthcare facilities for the period 
2014 - 2020. No significant difference in 
the slopes of number of patients diagnosed 
with HPT at clinic v. hospital level was 
found (p=0.781), but there was a significant 
difference in elevation between these slopes 
(p<0.001).
Figs 5 and 6 demonstrate that the majority 
of new patients with HPT, irrespective of 
age, were diagnosed and had their treatment 
initiated at clinic level.
A considerably greater number of patients 
aged ≥40 years were diagnosed with HPT 
compared with patients <40 years of age. 
This phenomenon was observed at both 
clinics and hospitals in KZN over the study 
period (Table 2).
Fig. 7 shows that a greater number of 
known hypertensive patients had consul-
tations at KZN clinics rather than hospitals 
over the study period (p<0.001).
Obesity remains a challenge in SSA. 
The present study showed that obesity 
was prevalent in both clinic and hospital 
patients, although to a significantly greater 
extent in patients visiting clinics rather than 
hospitals (Fig. 8). The study showed that 
obesity remains a problem in both rural and 
urban areas in KZN (Fig. 9).
Further sub-analysis of overall numbers 
of obese patients per 100  000 population 
per district using a Pareto chart revealed 
that >80% of the obesity burden at both 
KZN clinics and hospitals occurs outside 
the urbanised metro municipality (Figs 10 
and 11).
Significantly more patients were screened 
for HPT in rural than in urban areas during 
the study period (Fig. 12). This trend was 
similar in both the <40- and ≥40-year age 
groups. No significant difference in the 
slopes of number of patients screened for 
HPT at rural v. urban healthcare settings 
was found (p=0.769); however, there was a 
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Fig. 1. Overall number of patients screened for hypertension (in millions).
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Fig. 2. Number of patients aged <40 years screened for hypertension (in millions).
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Fig. 3. Number of patients aged ≥40 years screened for hypertension (in millions).
Table 1. Differences in hypertension screening for patients aged ≥40 and <40 years
<40 years, n ≥40 years, n p-value
Clinics
2017/18 5 538 000 3 884 218 <0.001
2018/19 6 553 364 4 013 218 <0.001
2019/20 3 687 566 2 138 231 <0.001
Hospitals
2017/18 423 348 506 456 <0.001
2018/19 607 569 604 948 0.452
2019/20 345 263 341 860 0.195
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significant difference in elevation between 
these slopes (p<0.001).
A similar trend (rural significantly higher 
than urban) was noted with regard to 
the overall number of new hypertensives 
diagnosed and treated (Fig. 13). No signifi-
cant difference in the slopes of number of 
patients diagnosed with HPT at rural v. urban 
health care settings was found (p=0.640), but 
a significant difference was noted in elevation 
between these slopes (p<0.001).
Discussion
HPT remains a global threat, and this threat is 
increasingly being highlighted by the current 
COVID-19 pandemic. Understanding the 
pattern of this NCD in KZN will allow 
us to plan effective interventional public 
health strategies to assist control efforts in a 
resource-limited developing country.
Our study demonstrates that, appro-
priately, screening for HPT is taking 
place at both public healthcare clinics and 
hospitals. It further reveals that the clinics 
were performing the bulk of HPT screening 
compared with hospitals (p<0.001), 
irrespec tive of patient age. Interestingly, 
a significantly greater number of patients 
aged <40 years compared with ≥40 years 
were being screened for HPT at clinic level 
(p<0.001). This bodes well for a disease in 
which early detection and treatment will 
delay or prevent long-term complications in 
the form of blindness, myocardial infarction 
and renal failure, and so decrease the burden 
on both individual patients and the economy 
of the country. It makes practical sense to 
understand that patients who are seen at 
hospital level for HPT or other comorbidities 
are generally older in age.
Results of studies relating to urban v. 
rural distribution of HPT in Africa and SA 
have been varied. Addo et al.,[26] in their 
systematic analysis of 25 studies conducted in 
SSA, found that the majority of hypertensive 
patients lived in urban areas. In contrast, 
Ntuli et al.[27] found a high prevalence of 
HPT in rural patients. The present study 
showed that the majority of new hypertensive 
patients initiated onto treatment were seen 
at clinic level, irrespective of patient age. We 
found, like Ntuli et al.[27] and Groenewald et 
al.,[37] that the majority of patients diagnosed 
with HPT were rural, over the entire time 
period and across both the <40- and ≥40-
year age groups (p<0.05).
Having identified that the majority of our 
new hypertensives are rural patients visiting 
clinics, we need to develop and intensify 
existing healthcare systems at this level 
to help  minimise the effects of the HPT 
pandemic. In 2009, Mayosi et al.[40] called for 
inte gration and strengthening of healthcare 
systems, particularly at the primary healthcare 
level. They also sug gested that SA should 
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Fig. 4. Number of new patients diagnosed with hypertension and having treatment initiated.
Table 2. Age distribution of patients diagnosed with hypertension in clinics and 
hospitals
<40 years, n ≥40 years, n p-value
Clinics
2017/18 30 743 35 414 <0.001
2018/19 26 355 28 612 0.002
2019/20 12 987 16 578 <0.001
Hospitals
2017/18 3 905 6 317 <0.001
2018/19 4 254 5 601 <0.001
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Fig. 6. Number of patients aged ≥40 years initiated on treatment for hypertension.
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develop a compre hensive national surveillance 
system that would be able to determine 
whether implemented intervention strategies 
for both communicable diseases and NCDs 
had real clinical impact. Pillay-van Wyk et 
al.[41] showed that while there was a decrease 
in the number of deaths attributable to HIV 
and TB in Cape Town between 2009 and 
2013, there was a simultaneous increase in the 
number of deaths attributable to NCDs. They 
suggested that an integrated national NCD 
strategy should be put into place to address 
reversing the effects of HPT and DM.[41] Our 
study revealed that the majority of patients 
with known HPT had their consultations at 
clinic level rather than at hospitals. These 
results mirror what Pillay et al.[42] found with 
regard to diagnosis and treatment .of DM in 
KZN. The results of our study support the 
justification for an integrated and improved 
primary healthcare system. Resources in the 
form of both staffing and equipment must be 
redirected towards this healthcare level as a 
matter of urgency, as it is where the majority 
of HPT patients are being diagnosed and have 
their treatment initiated.
Added to this cauldron of communicable 
diseases and NCDs, SA has the highest 
rate of obesity in SSA.[22] Obesity has been 
shown to be a major aetiological factor in 
the development of both HPT and DM, two 
of the most devastating NCDs.[29,30,35] Each 
of these three NCDs has been implicated 
in increased morbidity and mortality in 
patients infected with the coronavirus.[7-10] 
Results from our study showed that obesity 
was prevalent in both clinic and hospital 
hypertensive patients, in both urban and 
rural areas. Obesity is one of the most 
important modifiable risk factors for HPT 
that we must campaign against, in KZN and 
in SA as a whole, if we are to win the battle 
against NCDs. Although some studies have 
shown obesity to be an urban rather than 
a rural problem, a result of changes to a 
more westernised diet, we have shown that 
obesity is a major problem in rural KZN, 
which carries >80% of the obesity burden 
at both clinic and hospital level. This is 
extremely worrying, and probably reflects 
the poverty experienced in these rural areas, 
with consequent dependence on cheaper 
energy-dense foods and resultant obesity. 
Obesity is a precursor to both DM and HPT, 
two of the major NCDs globally. Urgent 
intervention strategies need to be developed 
to target obesity at all levels of healthcare, 
both in SA and worldwide.
There are currently no regulations in 
place in SA for annual health screening for 
asymptomatic adult patients. This lack is 
possibly a major reason why HPT or elevated 
blood pressure are only detected late in the 
course of the disease process in SA. This 
deficit in the current system can be alleviated 
by allowing community healthcare workers 
to do automated blood pressure readings 
and point-of-care glycosylated haemoglobin 
testing during their routine home visits, and 
if necessary, make appropriate referrals to 
local clinics. This strategy would provide 
a way to address both of the major NCDs 
(DM and HPT) simultaneously at community 
healthcare level, a level at which we and others 
have shown that most of the diagnosis and 
treatment of these conditions takes place.[42]
Study limitations
No DHIS data were collected on the number 
of patients with obesity and HPT. Possible 
lack of accuracy of data collected by each 
healthcare facility is also a limitation.
Conclusions
HPT and its complications remain a global 
threat. Understanding the burden that 
this NCD is posing in KZN would help in 
developing more effective public healthcare 
strategies.
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Fig. 7. Number of visits of known hypertensives (in millions).
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Fig. 9. Number of patients with obesity per 100 000 population, urban v. rural.
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Screening, diagnosis, initiation of treat-
ment and chronic HPT management are 
mainly taking place at rural clinic level. The 
government needs to heed these findings and 
redirect resources (staffing and equipment) 
to this level.
Obesity remains a global problem, and 
KZN has not been spared. We found that 
obesity was prevalent at both clinic and 
hospital healthcare level, but mainly in rural 
healthcare facilities, suggesting that we need 
to urgently upscale our efforts to curb the 
obesity pandemic.
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Fig. 10. Pareto chart showing total number of obese patients per 100 000 population per district seen in 
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Fig. 11. Pareto chart showing total number of obese patients per 100  000 population per district 
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Fig. 12. Overall number of patients screened for hypertension (in millions): urban v. rural.
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Fig. 13. Overall number of new hypertensives per 100 000 population, urban v. rural.
